CDK4 and bone metastasis: The univariate analysis included the following variables: age, Eastern Cooperative Oncology Group performance status (ECOG PS), menopausal status, visceral disease, bone metastasis, CDK4/6i type, number of metastatic sites, endocrine sensitivity or resistance status, dose reduction, and concomitant use of PPIs (Table 5).